Prothena Corporation plc PRTA
8.60 USD -0.18 (-1.99%)
Nov 10, 2026, 9:42 AM EST
8.53 Day range 8.69
7.73 52-week range 11.80
- YTD
- -9.95%
- 1 year
- -18.33%
News
defenseworld.net Prothena Corporation plc (NASDAQ:PRTA) Stock Has Average Target Price of $20.00 Shares of Prothena Corporation plc (NASDAQ: PRTA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the seven analysts that are covering the stock, Marketbeat.com…
benzinga.com CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.36) per share which missed the analyst consensus estimate of $(0.09) by 300 percent. This is a 79.19 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares…
benzinga.com Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Crown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results and raising its FY26 EPS guidance. Other gaining stocks include SLGB, HIHO, WNW, CHNR, RDGT, ULBI,…
benzinga.com UPDATED: Watching Prothena; Shares Spike Higher, Form4 Filing Shows William P. Scully Bought 100,000 Shares At An Average Price Of $9.81/Share https://www.sec.gov/Archives/edgar/data/1559053/000104546326000004/xslF345X06/primary_doc.xml
benzinga.com Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $20 Citizens analyst Jason N. Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $19 to $20.
benzinga.com Prothena Corp Q1 EPS $0.60 Beats $(0.34) Estimate, Sales $51.084M Beat $1.010M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $(0.34) by 276.47 percent. This is a 153.57 percent increase over losses of…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session 
benzinga.com Prothena Announces Coramitug Amyloid Depleter Antibody Receives FDA's Fast Track Designation To Treat ATTR Amyloidosis With Cardiomyopathy Prothena Corporation plc (NASDAQ:PRTA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to coramitug, a potential best-in-class amyloid depleter…
benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $12 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $11 to $12.
benzinga.com Prothena Corp Q4 Earnings Assessment 
benzinga.com Prothena Corp Q4 EPS $(0.40) Beats $(0.54) Estimate, Sales $21.000K Miss $1.334M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.40) per share which beat the analyst consensus estimate of $(0.54) by 25.93 percent. This is a 62.96 percent increase over losses of…
benzinga.com Earnings Scheduled For February 19, 2026 
benzinga.com Exploring Prothena Corp's Earnings Expectations 
benzinga.com Amazon To Rally Around 31%? Here Are 10 Top Analyst Forecasts For Monday 
benzinga.com Citizens Maintains Market Outperform on Prothena Corp, Raises Price Target to $19 Citizens analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and raises the price target from $11 to $19.
benzinga.com Prothena Data From TDP-43 CYTOPE Program Demonstrates CYTOPE Technology's Potential To Deliver Large Molecules Into Cells Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, announced a…
benzinga.com Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study.- benzinga.com Prothena Presents Phase 2 Clinical Study Data For Coramitug For Treatment Of ATTR Amyloidosis With Cardiomyopathy American Heart Association's Circulation Journal Prothena Corporation plc (NASDAQ:PRTA) announced the publication of Phase 2 clinical trial data for coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody, for the…
- benzinga.com HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $30 HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target from $20 to $30.
- benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Raises Price Target to $11 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and raises the price target from $10 to $11.
benzinga.com Prothena Corp Q3 Adj. EPS $(0.68) Beats $(0.69) Estimate, Sales $2.415M Miss $6.639M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.68) per share which beat the analyst consensus estimate of $(0.69) by 1.02 percent. This is a 38.18 percent increase over losses of…
benzinga.com Earnings Scheduled For November 6, 2025 - benzinga.com Piper Sandler Maintains Overweight on Prothena Corp, Raises Price Target to $36 Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and raises the price target from $15 to $36.
- benzinga.com Deep Dive Into Prothena Corp Stock: Analyst Perspectives (7 Ratings)
- benzinga.com HC Wainwright & Co. Maintains Buy on Prothena Corp, Raises Price Target to $20 HC Wainwright & Co. analyst Andrew S. Fein maintains Prothena Corp (NASDAQ:PRTA) with a Buy and raises the price target from $14 to $20.
- benzinga.com Prothena's Partner Bristol Myers Squibb Receives Fast Track Designation From The FDA For BMS-986446 For The Treatment of Alzheimer's Disease Prothena Corporation plc (NASDAQ:PRTA), announced today that Bristol Myers Squibb communicated in a press release that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation…
benzinga.com Alibaba To Rally More Than 12%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com JMP Securities Maintains Market Outperform on Prothena Corp, Lowers Price Target to $11 JMP Securities analyst Jason Butler maintains Prothena Corp (NASDAQ:PRTA) with a Market Outperform and lowers the price target from $29 to $11.
benzinga.com FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
benzinga.com Prothena Reports Non-Competitive Brain Swelling Rates In Early Alzheimer's Study Prothena reported ASCENT trial data showing strong amyloid plaque reduction but high ARIA-E rates for Alzheimer's drug PRX012, prompting a shift in focus.- benzinga.com Piper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $15 Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and lowers the price target from $81 to $15.
- benzinga.com What 4 Analyst Ratings Have To Say About Prothena Corp
- benzinga.com Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.
- benzinga.com Prothena Reports Phase 1 Results For PRX012 In Alzheimer's; Explores Partnerships To Advance PRX012 And TfR-Linked Preclinical Program As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibodyPhase 1 ASCENT clinical program…
- benzinga.com RBC Capital Maintains Sector Perform on Prothena Corp, Lowers Price Target to $10 RBC Capital analyst Brian Abrahams maintains Prothena Corp (NASDAQ:PRTA) with a Sector Perform and lowers the price target from $18 to $10.
- benzinga.com 9 Analysts Assess Prothena Corp: What You Need To Know
- benzinga.com HC Wainwright & Co. Reiterates Buy on Prothena Corp, Maintains $14 Price Target HC Wainwright & Co. analyst Andrew S. Fein reiterates Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $14 price target.
- benzinga.com Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.
- benzinga.com Prothena Corp Q2 Adj. EPS $(1.73) Misses $(1.27) Estimate, Sales $4.420M Miss $6.180M Estimate Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(1.73) per share which missed the analyst consensus estimate of $(1.27) by 36.01 percent. This is a 241.8 percent decrease over earnings of…
- benzinga.com Earnings Scheduled For August 4, 2025
- benzinga.com A Glimpse of Prothena Corp's Earnings Potential
- benzinga.com 8 Analysts Assess Prothena Corp: What You Need To Know
- benzinga.com Prothena Cuts Workforce By ~63% To Streamline Operations And Reduce Costs; Revises FY25 Financial Guidance Prothena Corporation plc (NASDAQ:PRTA) today announced that the Company has initiated an approximate 63% reduction in its workforce to substantially reduce its operating costs to those necessary to…
- benzinga.com Prothena and Roche Move Parkinson's Drug to Phase III in Bid for First Disease-Modifying Treatment Prothena Corporation plc (NASDAQ:PRTA) today announced partner Roche will advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development in early-stage Parkinson's…
- benzinga.com B of A Securities Downgrades Prothena Corp to Underperform, Lowers Price Target to $4 B of A Securities analyst Tazeen Ahmad downgrades Prothena Corp (NASDAQ:PRTA) from Neutral to Underperform and lowers the price target from $22 to $4.
benzinga.com Williams Companies To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Wednesday - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Piper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $81 Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and lowers the price target from $110 to $81.
benzinga.com PTC Therapeutics To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Tuesday